Suppr超能文献

眼科神经退行性疾病中的胞磷胆碱:综述

Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review.

作者信息

Oddone Francesco, Rossetti Luca, Parravano Mariacristina, Sbardella Diego, Coletta Massimo, Ziccardi Lucia, Roberti Gloria, Carnevale Carmela, Romano Dario, Manni Gianluca, Parisi Vincenzo

机构信息

IRCCS-Fondazione Bietti, Via Livenza, 3, 00198 Rome, Italy.

Eye Clinic, ASST Santi Paolo e Carlo, San Paolo Hospital, University of Milan, Via Antonio di Rudinì, 8, 20142 Milan, Italy.

出版信息

Pharmaceuticals (Basel). 2021 Mar 20;14(3):281. doi: 10.3390/ph14030281.

Abstract

Cytidine 5'-diphosphocholine has been widely studied in systemic neurodegenerative diseases, like Alzheimer's disease, Parkinson's disease, and brain ischemia. The rationale for the use of citicoline in ophthalmological neurodegenerative diseases, including glaucoma, anterior ischemic optic neuropathy, and diabetic retinopathy, is founded on its multifactorial mechanism of action and the involvement in several metabolic pathways, including phospholipid homeostasis, mitochondrial dynamics, as well as cholinergic and dopaminergic transmission, all being involved in the complexity of the visual transmission. This narrative review is aimed at reporting both pre-clinical data regarding the involvement of citicoline in such metabolic pathways (including new insights about its role in the intracellular proteostasis through an interaction with the proteasome) and its effects on clinical psychophysical, electrophysiological, and morphological outcomes following its use in ophthalmological neurodegenerative diseases (including the results of the most recent prospective randomized clinical trials).

摘要

胞苷5'-二磷酸胆碱已在全身性神经退行性疾病中得到广泛研究,如阿尔茨海默病、帕金森病和脑缺血。在包括青光眼、前部缺血性视神经病变和糖尿病视网膜病变在内的眼科神经退行性疾病中使用胞磷胆碱的理论依据,基于其多因素作用机制以及参与多种代谢途径,包括磷脂稳态、线粒体动力学以及胆碱能和多巴胺能传递,所有这些都与视觉传导的复杂性有关。本叙述性综述旨在报告关于胞磷胆碱参与此类代谢途径的临床前数据(包括通过与蛋白酶体相互作用在细胞内蛋白质稳态中作用的新见解),以及其在眼科神经退行性疾病中使用后对临床心理物理学、电生理学和形态学结果的影响(包括最新前瞻性随机临床试验的结果)。

相似文献

1
Citicoline in Ophthalmological Neurodegenerative Disease: A Comprehensive Review.
Pharmaceuticals (Basel). 2021 Mar 20;14(3):281. doi: 10.3390/ph14030281.
2
Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function.
Curr Neuropharmacol. 2018;16(7):919-932. doi: 10.2174/1570159X15666170703111729.
5
Cholinergic nervous system and glaucoma: From basic science to clinical applications.
Prog Retin Eye Res. 2019 Sep;72:100767. doi: 10.1016/j.preteyeres.2019.06.003. Epub 2019 Jun 23.
7
Pharmacodynamics of citicoline relevant to the treatment of glaucoma.
J Neurosci Res. 2002 Jan 15;67(2):143-8. doi: 10.1002/jnr.10129.
8
Citicoline: pharmacological and clinical review, 2006 update.
Methods Find Exp Clin Pharmacol. 2006 Sep;28 Suppl B:1-56.
10
Phospholipase A2, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia.
Antioxid Redox Signal. 2003 Oct;5(5):647-54. doi: 10.1089/152308603770310329.

引用本文的文献

1
Targeting Senescence, Oxidative Stress, and Inflammation: Quercetin-Based Strategies for Ocular Diseases in Older Adults.
Clin Interv Aging. 2025 Jun 7;20:791-813. doi: 10.2147/CIA.S516946. eCollection 2025.
2
Antioxidants in Age-Related Macular Degeneration: Lights and Shadows.
Antioxidants (Basel). 2025 Jan 27;14(2):152. doi: 10.3390/antiox14020152.
3
Neuroprotective Effect of the Combination of Citicoline and CoQ10 in a Mouse Model of Ocular Hypertension.
Antioxidants (Basel). 2024 Dec 24;14(1):4. doi: 10.3390/antiox14010004.
4
Ischemic Optic Neuropathy: A Review of Current and Potential Future Pharmacotherapies.
Pharmaceuticals (Basel). 2024 Sep 27;17(10):1281. doi: 10.3390/ph17101281.
5
Advances in Neuroprotection in Glaucoma: Pharmacological Strategies and Emerging Technologies.
Pharmaceuticals (Basel). 2024 Sep 25;17(10):1261. doi: 10.3390/ph17101261.
6
Glaucoma: Current and New Therapeutic Approaches.
Biomedicines. 2024 Sep 3;12(9):2000. doi: 10.3390/biomedicines12092000.
7
Restored retinal physiology after administration of niacin with citicoline in a mouse model of hypertensive glaucoma.
Front Med (Lausanne). 2023 Sep 5;10:1230941. doi: 10.3389/fmed.2023.1230941. eCollection 2023.
8
The Role of Citicoline and Coenzyme Q10 in Retinal Pathology.
Int J Mol Sci. 2023 Mar 7;24(6):5072. doi: 10.3390/ijms24065072.
9
Combined use of coenzyme Q10 and citicoline: A new possibility for patients with glaucoma.
Front Med (Lausanne). 2022 Dec 15;9:1020993. doi: 10.3389/fmed.2022.1020993. eCollection 2022.
10
Citicoline: pharmacological and clinical review, 2022 update.
Rev Neurol. 2022 Nov 30;75(s05):S1-S89. doi: 10.33588/rn.75s05.2022311.

本文引用的文献

1
Correlations between visual morphological, electrophysiological, and acuity changes in chronic non-arteritic ischemic optic neuropathy.
Graefes Arch Clin Exp Ophthalmol. 2021 May;259(5):1297-1308. doi: 10.1007/s00417-020-05023-w. Epub 2021 Jan 7.
3
P2X7 receptor antagonism preserves retinal ganglion cells in glaucomatous mice.
Biochem Pharmacol. 2020 Oct;180:114199. doi: 10.1016/j.bcp.2020.114199. Epub 2020 Aug 13.
5
Assessment of retinal neurodegeneration with spectral-domain optical coherence tomography: a systematic review and meta-analysis.
Eye (Lond). 2021 May;35(5):1317-1325. doi: 10.1038/s41433-020-1020-z. Epub 2020 Jun 24.
7
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Pharmacol Ther. 2020 Sep;213:107579. doi: 10.1016/j.pharmthera.2020.107579. Epub 2020 May 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验